---
layout: post
title: "Product-Specific Guidance for Oxymetazoline Hydrochloride; Draft Guidance for Industry; Availability"
date: 2026-02-05 19:08:57 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2024-06985
original_published: 2024-04-03 00:00:00 +0000
significance: 8.00
---

# Product-Specific Guidance for Oxymetazoline Hydrochloride; Draft Guidance for Industry; Availability

**Published:** February 05, 2026 19:08 UTC
**Source:** Federal Register
**Original Published:** April 03, 2024 00:00 UTC
**Document Number:** 2024-06985

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Draft Guidance on Oxymetazoline Hydrochloride." The draft guidance, when finalized, will provide product-specific recommendations on, among other things, the design of bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs) for oxymetazoline hydrochloride ophthalmic solution.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2024/04/03/2024-06985/product-specific-guidance-for-oxymetazoline-hydrochloride-draft-guidance-for-industry-availability)
- API: https://www.federalregister.gov/api/v1/documents/2024-06985

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
